• EI
  • Scopus
  • 食品科学与工程领域高质量科技期刊分级目录第一方阵T1
  • DOAJ
  • EBSCO
  • 北大核心期刊
  • 中国核心学术期刊RCCSE
  • JST China
  • FSTA
  • 中国精品科技期刊
  • 中国农业核心期刊
  • CA
  • WJCI
  • 中国科技核心期刊CSTPCD
  • 中国生物医学SinoMed
中国精品科技期刊2020
李霞,张国柱,刘志飞,等. 肠浒苔多糖降血糖活性研究[J]. 食品工业科技,2021,42(15):321−326. doi: 10.13386/j.issn1002-0306.2020090021.
引用本文: 李霞,张国柱,刘志飞,等. 肠浒苔多糖降血糖活性研究[J]. 食品工业科技,2021,42(15):321−326. doi: 10.13386/j.issn1002-0306.2020090021.
LI Xia, ZHANG Guozhu, LIU Zhifei, et al. Hypoglycemic Activity of Enteromorpha intestinalis Polysaccharide[J]. Science and Technology of Food Industry, 2021, 42(15): 321−326. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2020090021.
Citation: LI Xia, ZHANG Guozhu, LIU Zhifei, et al. Hypoglycemic Activity of Enteromorpha intestinalis Polysaccharide[J]. Science and Technology of Food Industry, 2021, 42(15): 321−326. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2020090021.

肠浒苔多糖降血糖活性研究

Hypoglycemic Activity of Enteromorpha intestinalis Polysaccharide

  • 摘要: 为探究肠浒苔多糖(Enteromorpha intestinalis polysaccharide,EIP)的降血糖活性,通过DEAE纤维素柱层析进行分离,测定了各组分的理化性质,研究了EIP-2组分对小鼠降血糖指标的影响。实验动物分为正常组、模型组、二甲双胍阳性组(50 mg/kg/day)、EIP-2低剂量组(50 mg/kg/day)、EIP-2中剂量组(100 mg/kg/day)、EIP-2高剂量组(200 mg/kg/day),连续灌胃5周。分别测定了小鼠体重、空腹血糖浓度、葡萄糖和胰岛素耐受量、血清胰岛素和脂质水平、肝脏抗氧化酶水平等。实验结果表明,EIP-2干预后,相比于模型组各剂量组小鼠体重极显著增加(P<0.001)、空腹血糖极显著降低(P<0.001)、葡萄糖和胰岛素耐受量得到改善。高剂量组血清游离脂肪酸水平较显著降低(P<0.01)、各剂量组血清胰岛素和甘油三酯水平降低且具有剂量依赖性。与模型组相比,各剂量组肝脏谷草转氨酶水平较显著降低(P<0.01)、谷丙转氨酶水平极显著降低(P<0.001)、超氧化物歧化酶水平较显著提高(P<0.01),低剂量组肝脏过氧化氢酶水平显著提高(P<0.05)。综上所述,肠浒苔多糖对T2DM小鼠的血糖调节、血脂代谢和肝脏氧化应激具有明显改善作用,这为肠浒苔多糖降血糖机制的研究和药物开发利用提供了参考依据。

     

    Abstract: In order to explore the hypoglycemic activity of Enteromorpha intestinalis polysaccharide, the components were separated by DEAE cellulose column chromatography and their physical and chemical properties were determined, and the effect of EIP-2 components on hypoglycemic indexes in mice was studied. The experimental animals were divided into normal group, model group, metformin positive group (50 mg/kg/day), EIP-2 low dose group (50 mg/kg/day), EIP-2 medium dose group (100 mg/kg/day), EIP-2 high dose group (200 mg/kg/day). The body weight, fasting blood glucose concentration, glucose and insulin tolerance, serum insulin and lipid levels, liver antioxidant enzyme levels were measured. The results showed that compared with the model group, the weight of mice in each dose groups was significantly increased (P<0.001), fasting blood glucose was significantly decreased (P<0.001), glucose and insulin tolerance were improved after EIP-2 intervention. The levels of serum nonestesterified fatty acid in high dose group were significantly lower than those in model group (P<0.01), and the levels of serum insulin and triglyceride were decreased in a dose-dependent manner. Compared with the model group, the liver aspartate aminotransferase level was significantly decreased (P<0.01), alanine aminotransferase level was significantly decreased (P<0.001), superoxide dismutase level was significantly increased (P<0.01), and the liver catalase level was significantly increased in the low-dose group (P<0.05). In summary, EIP can improve blood glucose regulation, blood lipid metabolism and liver oxidative stress in T2DM mice, which provides a reference for study of the hypoglycemic mechanism of EIP and the development and utilization of hypoglycemic drugs.

     

/

返回文章
返回